Название продукции:methyl 2-[(2-methylpropan-2-yl)oxycarbonylamino]-4-oxobutanoate

IUPAC Name:methyl 2-{[(tert-butoxy)carbonyl]amino}-4-oxobutanoate

CAS:87884-14-8
Молекулярная формула:C10H17NO5
Чистота:95%+
Номер в каталоге:CM679627
Молекулярная масса:231.25

Упаковочная единица Доступно для заказа Цена ($) Количество

Только для использования в НИОКР..

Форма запроса

   refresh    

Информация о продукции

Номер CAS:87884-14-8
Молекулярная формула:C10H17NO5
Точка плавления:-
Smiles-код:COC(=O)C(CC=O)NC(=O)OC(C)(C)C
Плотность:
Номер в каталоге:CM679627
Молекулярная масса:231.25
Точка кипения:
Номер Mdl:MFCD22681775
Хранение:

Category Infos

Aliphatic Chain Compounds
Aliphatic chain compounds include aliphatic compounds and chain compounds containing other elements or groups. Aliphatic hydrocarbons are hydrocarbons with the basic properties of aliphatic compounds. In aliphatic compounds, carbon atoms are arranged in straight chain, branched chain or cyclic, which are respectively called straight chain aliphatic hydrocarbons, branched chain aliphatic hydrocarbons and alicyclic hydrocarbons. Some cyclic hydrocarbons are different in nature from aromatic hydrocarbons, and are very similar to aliphatic hydrocarbons. Such cyclic hydrocarbons are called alicyclic hydrocarbons. In this way, aliphatic hydrocarbons become a general term for all hydrocarbons except aromatic hydrocarbons. Aliphatic hydrocarbons and their derivatives (including halogenated hydrocarbons) and alicyclic hydrocarbons and their derivatives are collectively referred to as aliphatic compounds.

Column Infos

Bexotegrast
Pliant announced positive safety and exploratory efficacy data from the INTEGRIS-PSC Phase 2a trial of Bexotegrast (PLN-74809) 320 mg in patients with primary sclerosing cholangitis and suspected liver ibrosis. PLN-74809 is an oral small-molecule dual-selective inhibitor of αvβ6 and αvβ1 integrins for the treatment of IPF and PSC. While present at very low levels in healthy tissues, these integrins are upregulated in the lungs of IPF patients and the bile ducts of PSC patients where they activate TGF-β, a key driver of the fibrotic process. Blocking these integrins is designed to stop TGF-β activation, potentially halting the growth of scar tissue.

Related Products